Articles published by Philogen S.p.A.

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus

June 10, 2025

From Philogen S.p.A.

Via GlobeNewswire

Tickers BMY

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

October 16, 2023

From Philogen S.p.A.

Via GlobeNewswire

Tickers BSE

Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS

April 12, 2021

From Philogen S.p.A.

Via AccessWire

Topics Derivatives

Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry

April 12, 2021

From Philogen S.p.A.

Via AccessWire

Philogen Announces Participation to the 10th World Congress of Melanoma

April 12, 2021

From Philogen S.p.A.

Via AccessWire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.